STOCK TITAN

Rapt Therapeutics, Inc. - RAPT STOCK NEWS

Welcome to our dedicated page for Rapt Therapeutics news (Ticker: RAPT), a resource for investors and traders seeking the latest updates and insights on Rapt Therapeutics stock.

Company Overview

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company focused on the discovery, development, and commercialization of oral small molecule therapies. Leveraging its proprietary discovery and development engine, the company is addressing significant unmet needs in both oncology and inflammatory diseases with a focus on modulating key immune drivers.

Core Business and Clinical Strategy

The company operates at the intersection of immunology and precision medicine, and is dedicated to the development of highly selective small molecules. Its innovative approach is centered on targeting the C-C motif chemokine receptor 4 (CCR4), a pivotal immune pathway implicated in the regulation of immune cell migration. By impeding the movement of regulatory T cells and type 2 T helper cells, RAPT aims to normalize immune responses in both cancer and inflammatory contexts.

Pipeline and Drug Candidates

RAPT Therapeutics has advanced multiple drug candidates through its development pipeline. Key assets include:

  • Tivumecirnon (FLX475): Designed to block the migration of regulatory T cells into tumors, potentially enhancing anti-tumor immune responses.
  • Zelnecirnon (RPT193): Engineered to inhibit the migration of specific T cell subsets into inflamed tissues, targeting inflammatory diseases.
  • RPT904: A clinical-stage anti-immunoglobulin E (IgE) antibody developed under a global licensing arrangement to address allergic disorders such as food allergy and chronic spontaneous urticaria.

Each candidate is a testament to the company’s commitment to precision pharmacology and medicinal chemistry, aiming to provide tailored therapeutic solutions while maintaining a robust platform for early-stage target discovery.

Research, Development, and Clinical Insights

Utilizing deep expertise in immunology, RAPT integrates rigorous scientific evaluation with methodical clinical development. Its research programs are designed to modulate immune responses by directly targeting critical pathways, and the company has steadily progressed in a highly competitive landscape. The strategic clinical trials encompass both monotherapy and combination approaches, allowing the company to assess therapeutic synergies and optimize clinical outcomes.

Competitive Positioning and Intellectual Rigor

Within the biopharmaceutical arena, RAPT stands apart by focusing on the modulation of immune cell migration. This strategy is particularly significant given the limitations of existing therapies in oncology and inflammatory conditions. The company’s methodical approach, which combines a proprietary discovery engine with precise clinical execution, establishes it as an informed participant in the competitive biotech sector. Its strategic partnerships and licensing deals further reinforce its commitment to diversifying and strengthening its therapeutic portfolio.

Business Model and Market Impact

The business model is built on robust R&D investment, strategic collaborations, and a well-structured pipeline aimed at delivering high specificity treatments. Investors can note the company’s methodical transition from early clinical trials to confirmation of pharmacodynamic effects, which supports its long-term mission to address critical immune-mediated conditions. RAPT Therapeutics represents a specialized venture into areas where there is a significant unmet need, thereby setting the stage for potential market differentiation through scientifically driven innovation.

Summary

RAPT Therapeutics is not just advancing a series of drug candidates; it is pioneering a targeted approach in the realm of immunology. Its clear focus on modulating specific immune mechanisms and its strategic clinical development make the company a subject of continued interest in the biopharmaceutical investment landscape. Through precise, selective targeting and rigorous clinical evaluation, RAPT demonstrates deep domain expertise and a commitment to addressing complex medical challenges.

Rhea-AI Summary

RAPT Therapeutics, a clinical-stage biopharmaceutical company, has announced a public offering of 3,787,879 shares at $33.00 each, aiming for approximately $125 million in gross proceeds. The offering, set to close on June 18, 2021, is managed by J.P. Morgan, SVB Leerink, and Piper Sandler. A 30-day option for underwriters to purchase an additional 568,181 shares is also available. This offering follows a shelf registration with the SEC that was effective on November 16, 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.07%
Tags
-
Rhea-AI Summary

RAPT Therapeutics, Inc. (Nasdaq: RAPT) has announced a public offering of $125 million in common stock, with an option for underwriters to purchase an additional $18.75 million. The offering is contingent on market conditions and is governed by a previously filed shelf registration statement with the SEC. J.P. Morgan, SVB Leerink, and Piper Sandler are the lead managers for the offering. This fundraising aims to support RAPT's development of oral therapies targeting significant unmet needs in oncology and inflammatory diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.07%
Tags
-
Rhea-AI Summary

RAPT Therapeutics announced positive topline results from its Phase 1b trial of RPT193 for moderate-to-severe atopic dermatitis. After four weeks, patients showed a 36.3% improvement in the Eczema Area and Severity Index (EASI) compared to 17.0% in the placebo group. Notably, a 53.2% improvement was recorded six weeks post-treatment. RPT193 was well tolerated with no serious adverse events. RAPT plans to advance RPT193 into a Phase 2b trial in atopic dermatitis and a Phase 2a trial in asthma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
115.51%
Tags
Rhea-AI Summary

RAPT Therapeutics (Nasdaq: RAPT) announced it will release top-line results from its Phase 1b clinical trial of RPT193 for moderate to severe atopic dermatitis on June 14, 2021. This key data announcement signifies the company's ongoing commitment to addressing unmet medical needs in inflammatory diseases. The results will be shared during a conference call at 8:30 a.m. ET, which will be accessible via a live webcast. RAPT is developing targeted oral therapies focusing on CCR4, with RPT193 as a notable candidate in its pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
115.51%
Tags
conferences clinical trial
-
Rhea-AI Summary

RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO Brian Wong will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 3:00 pm Eastern Time. The event aims to discuss the company’s advancements in developing oral small molecule therapies for oncology and inflammatory diseases. Interested parties can access the live webcast and archived recording on the RAPT Therapeutics website. The company is focused on developing selective small molecules targeting critical immune drivers, including drug candidates FLX475 and RPT193.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.25%
Tags
conferences
-
Rhea-AI Summary

RAPT Therapeutics reported a net loss of $16.5 million for Q1 2021, up from $13.1 million in Q1 2020. Research and development expenses rose to $13.8 million due to increased clinical trial costs and personnel expenses. General and administrative expenses increased to $4.0 million, impacted by higher stock-based compensation and insurance costs. The company is progressing in its oncology and inflammation programs, highlighting recent preclinical data and the completion of enrollment in a Phase 1b trial for RPT193. Cash and equivalents stood at $98.4 million as of March 31, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.08%
Tags
Rhea-AI Summary

RAPT Therapeutics has completed enrollment in its Phase 1b clinical trial of RPT193 for moderate to severe atopic dermatitis, with results expected by mid-2021. The trial aims to establish safety and clinical efficacy through multiple endpoints, including the Eczema Area and Severity Index and pruritis scale. An encouraging outcome may position RPT193 as a viable oral treatment option against existing injectable therapies, targeting significant unmet needs in inflammatory diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
-
Rhea-AI Summary

RAPT Therapeutics (Nasdaq: RAPT) announced its financial results for Q4 and the year ending December 31, 2020. The company reported a net loss of $12.7 million for Q4 2020, slightly better than the $13.2 million loss in Q4 2019. Annual net loss increased to $52.9 million from $43 million in 2019. Research and development expenses rose to $45.5 million in 2020, driven by clinical trial costs for FLX475 and RPT193. As of December 31, 2020, cash and equivalents totaled $111.5 million. Key clinical advancements were noted for both lead programs, with upcoming data readouts expected in 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.22%
Tags
-
Rhea-AI Summary

RAPT Therapeutics (RAPT) reported promising data from preclinical studies to be presented at the American Association for Cancer Research annual meeting. Key findings include the ability of CCR4 antagonists to enhance CAR T-cell therapy's efficacy in solid tumors, with a significant increase in survival rates in murine models. Additionally, small-molecule HPK1 inhibitors demonstrated enhanced T-cell responses, while GCN2 inhibitors showed potential to restore immunity in the tumor microenvironment. These developments highlight RAPT's ongoing commitment to advancing immunology-based therapies for cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.22%
Tags
conferences clinical trial
Rhea-AI Summary

SOUTH SAN FRANCISCO, Calif., March 3, 2021 - RAPT Therapeutics (Nasdaq: RAPT) announced CEO Brian Wong will speak at two investor conferences this month. The H.C. Wainwright Global Life Sciences Conference features a company presentation available on March 9 at 7:00 am ET. Wong will also participate in the 33rd Annual Roth Conference on March 15 at 2:00 pm ET, discussing novel immuno-oncology targets. RAPT specializes in oral small molecule therapies for oncology and inflammatory diseases, focusing on advanced drug candidates like FLX475 and RPT193.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
conferences

FAQ

What is the current stock price of Rapt Therapeutics (RAPT)?

The current stock price of Rapt Therapeutics (RAPT) is $1.17 as of April 1, 2025.

What is the market cap of Rapt Therapeutics (RAPT)?

The market cap of Rapt Therapeutics (RAPT) is approximately 155.1M.

What is the primary focus of RAPT Therapeutics, Inc.?

RAPT Therapeutics primarily focuses on discovering, developing, and commercializing oral small molecule therapies to address unmet needs in oncology and inflammatory diseases.

How does RAPT Therapeutics generate its drug candidates?

The company utilizes a proprietary discovery and development engine to create highly selective small molecules that modulate key immune drivers, particularly targeting the CCR4 pathway.

Which therapeutic areas does RAPT address?

RAPT addresses critical challenges in oncology by inhibiting tumor immune suppression, and in inflammatory diseases by modulating immune cell migration into inflamed tissues.

What distinguishes RAPT’s approach to drug development?

RAPT’s approach is distinguished by its focus on precision immunology, selective targeting of immune pathways, and a strategy that integrates both monotherapy and combination therapy clinical trials.

Can you explain the significance of the CCR4 target in their pipeline?

CCR4 plays a key role in regulating immune cell migration. By targeting this receptor, RAPT aims to prevent the infiltration of cells that suppress immune responses in cancer or exacerbate inflammation in chronic diseases.

What are some of the key drug candidates in RAPT's pipeline?

Key drug candidates include tivumecirnon (FLX475) for oncology, zelnecirnon (RPT193) for inflammatory conditions, and RPT904 which is aimed at allergic conditions such as food allergy and chronic spontaneous urticaria.

How does RAPT Therapeutics position itself within the competitive biopharmaceutical landscape?

RAPT is positioned as a specialized enterprise that applies targeted immunotherapy approaches. Its proprietary platform and strategic clinical development efforts underpin its competitive differentiation in areas of high unmet need.

What type of clinical trials does the company undertake?

The company conducts a range of clinical trials, including Phase 1/2 studies that integrate both monotherapy and combination regimens, aimed at evaluating safety, pharmacodynamics, and efficacy across various cancer and inflammatory disease indications.
Rapt Therapeutics, Inc.

Nasdaq:RAPT

RAPT Rankings

RAPT Stock Data

155.11M
99.83M
0.49%
96.43%
1.99%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO